Does immunosuppressive treatment entail an additional risk for children with rheumatic diseases? A survey-based study in
- PDF / 942,602 Bytes
- 11 Pages / 595.276 x 790.866 pts Page_size
- 71 Downloads / 147 Views
Rheumatology INTERNATIONAL
OBSERVATIONAL RESEARCH
Does immunosuppressive treatment entail an additional risk for children with rheumatic diseases? A survey‑based study in the era of COVID‑19 Oya Koker1 · Fatma Gul Demirkan1 · Gulsah Kayaalp1 · Figen Cakmak1 · Ayse Tanatar1 · Serife Gul Karadag2 · Hafize Emine Sonmez2 · Rukiye Omeroglu1 · Nuray Aktay Ayaz1 Received: 8 June 2020 / Accepted: 24 July 2020 © Springer-Verlag GmbH Germany, part of Springer Nature 2020
Abstract The aim of the research was to further extend current knowledge of whether severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) disease 2019 (COVID-19) entails a risk for children with various rheumatic diseases under immunosuppressive treatment. Telephone survey was administered by conducting interviews with the parents from May 1, 2020 to May 20, 2020. A message containing a link to the actual questionnaire was sent to their phones simultaneously. The medical records of the patients were reviewed for gathering information about demographic data, clinical follow-up, and treatments. Patients who were followed-up under immunosuppressive treatment (n = 439) were attempted to be contacted. The diagnostic distribution of patients (n = 414) eligible for the study was as follows: juvenile idiopathic arthritis (JIA) (n = 243, 58.7%), autoinflammatory diseases (n = 109, 26.3%), connective tissue diseases (n = 51, 12.3%), and vasculitis (n = 11, 2.7%). In the entire cohort, the mean age was 12 ± 4.7 years, and 54.1% (n = 224) were female. Nine patients have attended the hospital for COVID-19 evaluation, 6 of whom were in close contact with confirmed cases. One patient with seronegative polyarticular JIA, previously prescribed methotrexate and receiving leflunomide during pandemic was identified to be diagnosed with COVID-19. None, including the confirmed case, had any severe symptoms. More than half of the patients with household exposure did not require hospitalization as they were asymptomatic. Although circumstances such as compliance in social distancing policy, transmission patterns, attitude following contact may have influenced the results, immunosuppressive treatment does not seem to pose an additional risk in terms of COVID-19. Keywords Biological therapies · COVID-19 · Dmards · Immunosuppressants · Paediatric rheumatology
Introduction Severe acute respiratory syndrome coronavirus-2 (SARSCoV-2) disease 2019 (COVID-19), first reported from the Wuhan city of China in December 2019, swept the world in a few months and became a global health emergency Electronic supplementary material The online version of this article (https://doi.org/10.1007/s00296-020-04663-9) contains supplementary material, which is available to authorized users. * Nuray Aktay Ayaz [email protected] 1
Department of Paediatric Rheumatology, Istanbul Faculty of Medical School, Istanbul University, Istanbul, Turkey
Department of Paediatric Rheumatology, Kanuni Sultan Süleyman Research and Training Hospital, Istanbul, Turkey
2
of primary i
Data Loading...
